RESUMO
INTRODUCTION: Hepatitis B virus infection (VHB) is a serious condition which can lead to serious complications, such as cirrhosis and hepato-cellular carcinoma (HCC). HBV genotypes greatly influence its evolution and the effectiveness of treatment. The aim was to evaluate the HBV genotypes and the evolutionary pathways of chronic HBsAG patients. METHODS: A cross-sectional study was conducted at the University Hospital of Kamenge and at the Digestive and liver diseases Center "CEMADIF" between June 2013 and Mai 2014. Genotyping, quantitative assay of HBeAG and HBV DNA levels were determined in the CERBA Laboratory Cergy Pontoise, France. Fibrotest or Fibroscan were used to evaluate fibrosis. RESULTS: In total 33 patients (52,4% were males, median age 38,1) were enrolled. According to evolutionary markers, 112 patients (78,3%) had negative HBeAG. As regards the viral load, 106 patients (74,2%) had viremia lower than 2000UI/ml and minimal fibrosis below 7 kPa according FibroScan. Of these, 13 patients had undetectable HBV DNA (<20UI/ml). The others 37 patients (26,8%) had a viral load higher than 2000UI/ml and, among them, 31 were HBeAg positive(>0,8UI/ml). It was possible to determine genotype in 51 patients who had a high enough viremia to technically enable dosing. These patients had genotype A. CONCLUSION: HBV genotype-A is the most common in Bujumbura. It is associated with HBV inactive carries.
Assuntos
Antígenos E da Hepatite B/genética , Vírus da Hepatite B/genética , Hepatite B Crônica/virologia , Adulto , Burundi/epidemiologia , Estudos Transversais , DNA Viral , Feminino , Genótipo , Antígenos de Superfície da Hepatite B/genética , Hepatite B Crônica/epidemiologia , Humanos , Masculino , Carga Viral , Viremia/virologiaAssuntos
Carcinoma Hepatocelular/epidemiologia , Hepatite B Crônica/complicações , Cirrose Hepática/epidemiologia , Neoplasias Hepáticas/epidemiologia , Adulto , Carcinoma Hepatocelular/patologia , Carcinoma Hepatocelular/virologia , Estudos de Coortes , Progressão da Doença , Feminino , Humanos , Incidência , Cirrose Hepática/patologia , Cirrose Hepática/virologia , Neoplasias Hepáticas/patologia , Neoplasias Hepáticas/virologia , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Índice de Gravidade de DoençaRESUMO
INTRODUCTION: Hepatitis C virus (HCV) infection is a major public health issue. HCV genotype identification is clinically important to tailor the dosage and duration of treatment. Indeed, distinct therapeutic approaches are required for each genotype. Up to now, there is no study assessing HCV genotypes and subtypes in Burundi. The aim of the study was to determine HCV genotypes and subtypes in Burundi and to highlight the difficulties related to LiPA Method, widely used for African samples. METHODS: In this study, a total of 179 samples contained anti-HCV antibodies were tested for HCV RNA, genotyping and subtyping. The analysis had been made in Cerba laboratory, Paris, France. RESULTS: 166 patients (92.7%) were genotype 4; 10 patients (5.6%) were genotype 1 and 3 patients (1.7%) were genotype 3. It was possible to determine subtypes for 51 HCV-4 (30.7%) patients. Among these, 25 (49.1%) had 4h subtype; 11 (21.6%) had 4e subtype; 2 (3.9%) had 4k subtype and 13 patients (25.5%) had 4a/4c/4d subtype. The LiPA method failed to subtype 115 (69.3%) HCV-4 and to separate the three subtype: 4a, 4c and 4d. CONCLUSION: Genotype 4 and subtype 4h followed by 4e are the widespread in Burundi.
